Immunotherapy of cancer: are we already there?
Main Article Content
Abstract
Recent status in cell-based cancer therapy, humoral-based cancer therapy and cancer vaccines will be discussed in short; This will be followed by presentation of data in chimeric antigen receptor (CAR)-therapy employing targeting moieties based on modified ERBB receptors’ ligands. The activity and efficacy of modified EGF-like domains derived from NRG1 (ligand to ErbB3 (HER3) receptor) and betacellulin (ligand to ErbB1 (EGFR) receptor) ligands as targeting moiety in CAR therapy will be presented.
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Porgador A. Immunotherapy of cancer: are we already there?. SEE J Immunol [Internet]. 2025 Mar. 25 [cited 2026 Nov. 17];8(CITIM):048. Available from: https://seejim.eu/index.php/seejim/article/view/6110
Section
Invited lectures

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.